Disposition of 1577 shares by Graf Finckenstein Friedrich of Iovance Biotherapeutics at 8.37 subject to Rule 16b-3

IOVA Stock  USD 5.35  0.01  0.19%   
About 61% of Iovance Biotherapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Iovance Biotherapeutics suggests that many traders are alarmed. The current market sentiment, together with Iovance Biotherapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Iovance Biotherapeutics stock news signals to limit their universe of possible portfolio assets.
  
Filed transaction by Iovance Biotherapeutics Officer Chief Medical Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3

Read at macroaxis.com
Disposition of 1577 common stock at 8.37 of Iovance Biotherapeutics by Graf Finckenstein Friedrich on 4th of June 2024. This event was filed by Iovance Biotherapeutics with SEC on 2024-01-16. Statement of changes in beneficial ownership - SEC Form 4

Iovance Biotherapeutics Fundamental Analysis

We analyze Iovance Biotherapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Iovance Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Iovance Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

EBITDA

EBITDA Comparative Analysis

Iovance Biotherapeutics is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Iovance Biotherapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Iovance Biotherapeutics stock to make a market-neutral strategy. Peer analysis of Iovance Biotherapeutics could also be used in its relative valuation, which is a method of valuing Iovance Biotherapeutics by comparing valuation metrics with similar companies.

Complementary Tools for Iovance Stock analysis

When running Iovance Biotherapeutics' price analysis, check to measure Iovance Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iovance Biotherapeutics is operating at the current time. Most of Iovance Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Iovance Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iovance Biotherapeutics' price. Additionally, you may evaluate how the addition of Iovance Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
CEOs Directory
Screen CEOs from public companies around the world
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk